Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Sponsor: Verve Therapeutics, Inc.
Summary
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
Official title: Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
85
Start Date
2024-04-30
Completion Date
2027-08
Last Updated
2026-04-01
Healthy Volunteers
No
Interventions
VERVE-102
Intravenous (IV) infusion
Locations (22)
Clinical Study Center
Dothan, Alabama, United States
Clinical Study Center
Pomona, California, United States
Clinical Study Center
Boca Raton, Florida, United States
Clinical Study Center
Jacksonville, Florida, United States
Clinical Study Center
Winter Park, Florida, United States
Clinical Study Center
High Point, North Carolina, United States
Clinical Study Center
DeSoto, Texas, United States
Clinical Study Center
Renton, Washington, United States
Clinical Study Center
Adelaide, Australia
Clinical Study Center
Melbourne, Australia
Clinical Study Center
Sydney, Australia
Clinical Study Center
Chicoutimi, Canada
Clinical Study Center
Montreal, Canada
Clinical Study Center
Toronto, Canada
Clinical Study Center
Vancouver, Canada
Clinical Study Center
Rehovot, Israel
Clinical Study Center
Christchurch, New Zealand
Clinical Study Center
Birmingham, United Kingdom
Clinical Study Center
Edinburgh, United Kingdom
Clinical Study Center
London, United Kingdom
Clinical Study Center
Manchester, United Kingdom
Clinical Study Center
Nottingham, United Kingdom